HBK Sorce Advisory LLC Takes Position in Medpace Holdings, Inc. $MEDP

HBK Sorce Advisory LLC acquired a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, Holdings Channel.com reports. The firm acquired 4,309 shares of the company’s stock, valued at approximately $2,533,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Geneos Wealth Management Inc. grew its holdings in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. Elyxium Wealth LLC bought a new position in shares of Medpace in the fourth quarter worth about $30,000. Allied Private Wealth LLC bought a new position in shares of Medpace in the second quarter worth about $31,000. Basecamp Wealth Advisors LLC lifted its position in shares of Medpace by 187.5% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after buying an additional 45 shares in the last quarter. Finally, Quarry LP bought a new position in shares of Medpace during the 3rd quarter valued at approximately $35,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Medpace

In related news, CEO August J. Troendle sold 458 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $600.39, for a total value of $274,978.62. Following the completion of the sale, the chief executive officer directly owned 603,978 shares of the company’s stock, valued at $362,622,351.42. This represents a 0.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Susan E. Burwig sold 7,500 shares of the company’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the sale, the vice president owned 62,984 shares of the company’s stock, valued at approximately $37,790,400. This represents a 10.64% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 67,195 shares of company stock valued at $37,989,998 over the last 90 days. 20.50% of the stock is owned by corporate insiders.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $578.50 on Monday. The company has a market cap of $16.15 billion, a price-to-earnings ratio of 33.91, a PEG ratio of 2.58 and a beta of 1.15. The company has a 50-day moving average price of $536.23 and a 200 day moving average price of $491.58. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the prior year, the firm posted $3.10 earnings per share. The business’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on MEDP. Royal Bank Of Canada increased their target price on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Mizuho lifted their price target on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Finally, TD Cowen raised their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, Medpace has an average rating of “Hold” and a consensus target price of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.